Drugs / IMM01
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05860075 | Nov 2019 → Oct 2022 | hematopoietic and lymphoid cell neoplasm | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Terminated | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07170787 | Oct 2025 → Feb 2029 expected | cancer | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05833984 | May 2022 → Feb 2024 | classic Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05140811 | Jan 2022 → Feb 2024 | acute myeloid leukemia, myelodysplastic syndrome | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Unknown | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06647862 | Nov 2024 → Apr 2026 overdue | chronic myelomonocytic leukemia | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06465446 | Jun 2024 → Jun 2026 overdue | classic Hodgkin lymphoma | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IMM01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05860075 ↗ |
| Action | Inhibit | “IMM01(Anti-CD47 Recombinant Protein)” NCT07170787 ↗ |
| Modality | Protein / enzyme biologic | “IMM01 is a recombinant human signal regulatory protein α (SIRPα) IgG1 fusion protein” NCT05860075 ↗ |
| Route | Intravenous | “IMM01 is intravenously once a week” NCT05140811 ↗ |